Florian Wittlinger

MedicineBiochemistry, Genetics and Molecular BiologyChemistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 16 papers. Top paper: “Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor”.

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

ChemRxiv(2020)10.26434/chemrxiv.13416452

N/A

0DataRank · unranked

1 citations

david heppner, Ciric To, Marcel C. Guenther, Bo Hee Shin, Jaimin K Rana +6 more

Molecular Design of a “Two-in-One” Orthosteric-Allosteric Chimeric Mutant Selective EGFR Inhibitor

(2020)10.26434/chemrxiv.13416452.v1

N/A

0DataRank · unranked

0 citations

David E. Heppner, Ciric To, Marcel C. Guenther, Bo Hee Shin, Jaimin K Rana +6 more

Design of a “Two-in-One” Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.1c00848

N/A

0DataRank · unranked

43 citations

David E. Heppner, Ciric To, Marcel Günther, Bo Hee Shin, Jaimin K. Rana +13 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5-v2

N/A

0DataRank · unranked

3 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448)

ChemRxiv(2022)10.26434/chemrxiv-2022-5m8h5

N/A

0DataRank · unranked

0 citations

Tyler S. Beyett, Tatiana Shaurova, Calvin Pham, Florian Wittlinger, Ilse K. Schaeffner +6 more

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors

Methods in enzymology on CD-ROM/Methods in enzymology(2023)10.1016/bs.mie.2023.03.013

N/A

0DataRank · unranked

8 citations

Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan Laufer, David E. Heppner +1 more

Examining molecular factors of inactive versus active bivalent EGFR inhibitors: A missing link in fragment-based drug design.

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Calvin D. Pham, Ilse K. Schaeffner, Surbhi P. Chitnis, Tahereh Damghani +12 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-cs3xn-v2

N/A

0DataRank · unranked

3 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-tkqqk

N/A

0DataRank · unranked

2 citations

Daniel A. Urul, Blessing C. Ogboo, Florian Wittlinger, Stefan Laufer, Erik Schaefer +3 more

The origin of potency and mutant-selective inhibition by bivalent ATP-allosteric EGFR inhibitors

ChemRxiv(2023)10.26434/chemrxiv-2023-zzfc3

N/A

0DataRank · unranked

2 citations

Surbhi P. Chitnis, Calvin D Pham, Tahereh Damghani, Ilse K. Schaeffner, Matthew Q. Deng +13 more

Structural elements that enable specificity for mutant EGFR kinase domains with next-generation small-molecule inhibitors.

ChemRxiv(2023)10.26434/chemrxiv-2023-v522v

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Tyler S. Beyett, Michael J. Eck, Stefan Laufer, David E. Heppner +1 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Research Square(2023)10.21203/rs.3.rs-3286949/v1

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin Pham +15 more

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors

Communications Chemistry(2024)10.1038/s42004-024-01108-3

N/A

0DataRank · unranked

24 citations

Blessing C. Ogboo, Ekaterina Shevchenko, Tahereh Damghani, Calvin D. Pham, Ilse K. Schaeffner +15 more

Tilting the Scales toward EGFR Mutant Selectivity: Expanding the Scope of Bivalent “Type V” Kinase Inhibitors

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c02311

N/A

0DataRank · unranked

8 citations

Surbhi P. Chitnis, Calvin D. Pham, Tahereh Damghani, Kishan B. Patel, Mareike Möllers +17 more

Structure–Activity Relationships of Inactive‐Conformation Binding EGFR Inhibitors: Linking the ATP and Allosteric Pockets

Archiv der Pharmazie(2025)10.1002/ardp.70027

N/A

0DataRank · unranked

5 citations

Florian Wittlinger, Mareike Möllers, Tyler J. Hartman, Marcel Günther, Michael J. Eck +3 more

Structure-activity relationships of inactive-conformation binding EGFR inhibitors: Linking the ATP and allosteric pockets

ChemRxiv(2025)10.26434/chemrxiv-2025-2cdjb

N/A

0DataRank · unranked

0 citations

Florian Wittlinger, Mareike Möllers, Tyler J. Hartman, Marcel Günther, Michael J. Eck +3 more